Address And Details

1585 Broadway , New York, NY 10036
Fund Manager Team Managed
Manager Tenure

Strategy And Objective

The Inception Portfolio (the Fund ) seeks long-term capital appreciation by investing primarily in growth-oriented equity securities of small capitalization companies. Under normal market conditions, the Adviser seeks to achieve the Fund s investment objective by investing primarily in established and emerging companies with capitalizations within the range of companies included in the Russell 2000 Growth Index. As of December 31, 2019, these market capitalizations ranged between $11.2 million and $7.3 billion.

Net Asset Value

as of 5:44 PM ET 09/24/2021

Performance

  • 1 Week
  • -0.49%
  • 1 Month
  • +1.66%
  • 3 Months
  • -9.12%
  • 1 Yr Return
  • +63.46%
  • 5 Yr Return
  • +64.66%

Equity Sector Breakdown

Technology 22.36%
RetailTrade 19.65%
Health 10.09%
Finance 9.86%
NonDurables 6.26%
ConsumerDurables 2.57%
Services 1.41%
IndustrialCyclical 0.86%
Energy 0.27%
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Stocks 84.11%
ForeignStocks 4.88%
Other 1.39%
Preferred 0.72%
Cash 0.00%
Bonds 0.00%
Convertible 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 2.54 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha 24.29 12.97 n/a
Beta 1.45 1.38 n/a
R Squared 0.42 0.39 n/a
Std Deviation 41.22 32.98 n/a
Sharpe Ratio 1.42 1.26 n/a

Purchase Information

as of 5:52 PM ET 09/23/2021
Minimum Initial n/a
Minimum Additional $99
Minimum Initial IRA $99

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +74.38%
  • +137.44%
+74.38% +137.44%
3 Year
  • +48.82%
  • +58.30%
+48.82% +58.30%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +22.25%
  • +24.00%
+22.25% +24.00%

Top 10 Holdings

Symbol Company Name % Of Assets
RDFN REDFIN CORPORATION 4.75%
FSLY FASTLY INC 3.80%
SKLZ SKILLZ INC 3.70%
OSTK OVERSTOCK.COM 3.44%
VRM VROOM INC 3.41%
SFIX STITCH FIX INC 3.30%
VIC VICTORIAN PLUMBING GROUP PLC 2.74%
CVET COVETRUS INC 2.70%
NSTG NANOSTRING TECHNOLOGIES INC 2.66%
APPF APPFOLIO INC 2.40%

Recent Articles from TheStreet

wynn resorts broll

Jim Cramer Talks Macao With Wynn Resorts CEO

Matthew Maddox argues China's crackdown will lead to better regulation.

Tesla Lead

Experts Say the Disruptive Electric Vehicle Revolution is Here

See the latest news for the top stocks in the electric vehicle space including Tesla, Ford, General Motors, Li Auto and more.

Nikola

Tim Collins on How to Trade Nikola

Technical setups and short interest make much hated name volatile, and therefore interesting.

Chinese Firms Should Face Faster US Stock Delisting Over Audit Rules, SEC Chairman Gary Gensler Tells Lawmakers

Jim Cramer: Gensler's Plate is Very Full

SEC Chairman is key player in efforts to rein in ceaseless financial engineering.

stocks rise asset management sh

Cramer's Mad Money Recap: Advanced Micro Devices, Nvidia, Thor

Jim Cramer has your game plan for next week, which he says will be the calm before the earnings season storm.

Jim Cramer: Starbucks Needs More Traffic in Stores

Starbucks Resists Union Effort in New York Region: Report

Starbucks reportedly said it will raise wages and benefits and a union isn’t needed, to employees at three stores in Buffalo New York.

Exxon Mobil

Exxon, Occidental, Baker Hughes Make Goldman Turnaround List

Exxon has 'reduced costs, surprised to the downside on capital spending, outperformed our expectations in downstream/chemicals,' Goldman said.

videoblocks-a-series-of-fullhd-close-up-rotating-slider-dollymacro-shots-of-the-surface-of-computer-hardware-parts-chipsmotherboardcpucurcuits-close-up-macro-computer-chips-circuits-surface-rotating-dolly_s_mt0i43g_1080__D

Jim Cramer is Tired of the Weak Response to Chip Shortages

Companies need to forget about help from Washington and step up to the plate.

Microsoft Lead

Why 'Sarge' Guilfoyle Isn't Selling His Microsoft

Sharp management and strength across its business lines are keys to software giant.

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Bret Jensen: Paratek Deal Shows Promise

While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.